Search company, investor...
Hemovent company logo


Founded Year



Acquired | Acquired

Total Raised


About Hemovent

Hemovent is a medical device company that has develops a self-contained and portable Extra Corporeal Membrane Oxygenation (ECMO) system that supports or replaces heart and lung function in the event of cardiac and respiratory failure. On October 4th, 2021, Hemovent was acquired by MicroPort Scientific Corporation. Terms of the transaction were not disclosed.

Headquarters Location

Rottstrasse 33

Aachen, 52068,


+49 241 990 133 0

Missing: Hemovent's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hemovent's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Hemovent

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hemovent is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Hemovent Patents

Hemovent has filed 8 patents.

The 3 most popular patent topics include:

  • Cardiac surgery
  • Medical equipment
  • Fluid dynamics
patents chart

Application Date

Grant Date


Related Topics




Cardiac anatomy, Cardiac surgery, Cardiology, Congenital heart defects, Cardiovascular physiology


Application Date


Grant Date



Related Topics

Cardiac anatomy, Cardiac surgery, Cardiology, Congenital heart defects, Cardiovascular physiology



Latest Hemovent News

New Management Team at Hemovent

Nov 1, 2022

New Management Team at Hemovent Search jobs New Management Team at Hemovent Hemovent GmbH continues to grow. Starting in October, the new CEO and CMO Dr. Jürgen O. Böhm will join Christof Lenz and Dr. Oliver Marseille in the company’s management team. With immediate effect, Dr. Jürgen O. Böhm will take on the role of corporate management at Hemovent GmbH. As the new Chief Executive Officer and Chief Medical Officer, he will support for the two previous Managing Directors and Founders Christof Lenz (CFO) and Dr. Oliver Marseille (CTO). The medical technology company with around 35 employees is thus gaining an experienced expert to expand its corporate development. Hemovent is prepared for the next growth phase thanks to this strategic addition to its management team. “We are very glad that we were able to recruit Jürgen Böhm for Hemovent. His many years of experience using ECLS products and his expertise in corporate management and sales will help us to achieve our goals even more efficiently – of that I am sure,” said Christof Lenz, who is taking on a new role as CFO, effective immediately. Dr. Böhm specialized in heart surgery and has over 12 years of clinical experience. He started his career in medical device industry as the Clinical Director at Maquet Cardiopulmonary AG. For the last 10 years he was a member of the Xenios AG Executive Board, where he was responsible for Clinical Affairs and Operations. He also drove and supported corporate development and realized innovative solutions for the treatment of heart and lung failure. “I am very much looking forward to the new challenge of working at Hemovent. Christof Lenz and Oliver Marseille created an extremely innovative product, laying the foundation for entering the market and further sales growth. Now the successful market launch of the MOBYBOX™ System and consistent further development of our business are the highest priorities,” said Dr. Böhm. Editor Details is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. follow us Version: 2022.9.21.3 You are leaving Disclaimer: You are now leaving website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the website and will be redirected to another site. These sites are not under the control of is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Also, please be aware that the security and privacy policies on these sites may be different than policies, so please read third party privacy and security policies closely. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly. Continue

Hemovent Frequently Asked Questions (FAQ)

  • When was Hemovent founded?

    Hemovent was founded in 2013.

  • Where is Hemovent's headquarters?

    Hemovent's headquarters is located at Rottstrasse 33, Aachen.

  • What is Hemovent's latest funding round?

    Hemovent's latest funding round is Acquired.

  • How much did Hemovent raise?

    Hemovent raised a total of $19.84M.

  • Who are the investors of Hemovent?

    Investors of Hemovent include MicroPort Scientific Corporation, MIG Verwaltungs, KfW, Seed Fonds Aachen, Peter Borges and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.